The story of Sildenafil presents a complex case for investors in the drug sector. While initially a phenomenal success, generating billions, the intellectual property lapse and the subsequent arrival of off-brand versions have drastically impacted income. This presents questions about the ongoing profitability of analogous drug innovations and s… Read More